Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 9/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894671 | 1.00 | ADRA1D (0.47) | ADRA1DADRA1AADRA1BLMNAHTR1A | |
| SCHEMBL6221416 | 1.00 | ADRA1D (0.47) | ADRA1DADRA1AADRA1BLMNAHTR1A | |
| SCHEMBL4960952 | 0.91 | LMNA (0.43) | ADRA1DADRA1AADRA1BLMNAHTR1A | |
| SCHEMBL3888210 | 0.89 | HTR1A (0.45) | ADRA1DADRA1AADRA1BLMNAHTR1A | |
| SCHEMBL6742214 | 0.89 | HTR1A (0.45) | ADRA1DADRA1AADRA1BLMNAHTR1A | |
| SCHEMBL4960706 | 0.89 | ADRA1D (0.43) | ADRA1DADRA1AADRA1BLMNAHTR1A | |
| SCHEMBL6976444 | 0.89 | LMNA (0.48) | LMNASMN1; SMN2 | |
| SCHEMBL7782073 | 0.89 | LMNA (0.48) | LMNASMN1; SMN2 | |
| SCHEMBL6976439 | 0.89 | LMNA (0.48) | LMNASMN1; SMN2 | |
| SCHEMBL8225934 | 0.88 | LMNA (0.46) | ADRA1DADRA1AADRA1BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063728-A1 | 8-AZA-bicyclo[3.2.1]octan-3-OL derivative of 2,3-dihydro-1,4-benzodioxan as 5-HT 1A antagonists | WYETH | 2004-04-01 | — | — | US | disclosed |
| US-6656951-B2 | Treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease, or schizophrenia; also anxiety, aggression and stress; controlling appetite, thermoregulation, sleep and sexual behavior | WYETH | 2003-12-02 | — | — | US | disclosed |
| US-20030032648-A1 | 8-Aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benodioxan as 5-HT1A antagonists | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2002085900-A1 | 8-AZA-BICYCLO[3.2.1]OCTAN-3-OL DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063728-A1 | 8-AZA-bicyclo[3.2.1]octan-3-OL derivative of 2,3-dihydro-1,4-benzodioxan as 5-HT 1A antagonists | HTR5A, HTR1A, HTR1D | ADRA1D 20/4885ADRA1A 24/4885ADRA1B 41/4885 |
| US-20030032648-A1 | 8-Aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benodioxan as 5-HT1A antagonists | HTR5A, HTR1D, HTR1A | ADRA1D 14/4885ADRA1A 32/4885ADRA1B 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.